Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition

Coats, JT; Tauro, S; Sutherland, C

Sutherland, C (通讯作者)，Univ Dundee, Ninewells Hosp & Med Sch, Sch Med, Div Cellular & Syst Med, Dundee, Scotland.

CELL COMMUNICATION AND SIGNALING, 2023; 21 (1):

Abstract

Elraglusib (formerly 9-ING-41) is an ATP-competitive inhibitor of glycogen synthase kinase-3 ss (GSK3 ss) undergoing clinical trials for the treatment......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索